^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)

i
Other names: HNRNPAB, Heterogeneous Nuclear Ribonucleoprotein A/B, ABBP1, HNRPAB, APOBEC1-Binding Protein 1, HnRNP A/B, FLJ40338, ABBP-1, Apolipoprotein B MRNA Editing Enzyme, Catalytic Polypeptide 1-Binding Protein 1, Apobec-1 Binding Protein 1, HnRNP Type A/B Protein
2ms
Comparative Binding Analysis by Computational Methods and Quartz Crystal Microbalance: Case of hnRNPA2B1 Protein and Irinotecan Drug. (PubMed, J Chem Inf Model)
Further computational analysis via molecular docking and molecular dynamics (MD) simulations demonstrated stable binding of IRT to the RNA recognition domain (RRM) of hnRNPA2B1, yielding a binding free energy ΔG of -10.36 kcal·mol-1. These findings suggest that IRT may exert an inhibitory effect on hnRNPA2B1, potentially contributing to its anticancer activity beyond topoisomerase 1 inhibition.
Journal
|
HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)
|
irinotecan
2ms
1,2,3,6-Tetragalloylglucose inhibits hnRNPA2B1/TRAIL Axis to attenuate apoptosis and barrier dysfunction in intestinal epithelial cells: A potential therapeutic avenue for IBD. (PubMed, Cell Signal)
The study results suggest that A2B1 plays a crucial role in IBD by modulating TRAIL mRNA, leading to IECs apoptosis and intestinal barrier dysfunction. Targeting the A2B1-TRAIL interaction with small-molecule inhibitors like TeGG offers a novel and promising therapeutic approach for the treatment of IBD.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)
2ms
The Interaction of CircESR1 and HNRNPAB Regulates Cell Cycle Transition of Breast Cancer Cell. (PubMed, Int J Biol Sci)
Combined use of circESR1 ASO and CDK4/6 inhibitors were shown to be an effective therapeutic approach overcoming antiestrogen resistance in breast cancer xenograft models. Hence, these findings elucidated a novel signaling complex centered around circESR1 and HNRNPAB in ER+ breast cancer, and suggested that circESR1 might represent a potential therapeutic target for this disease.
Journal
|
ER (Estrogen receptor) • CDK1 (Cyclin-dependent kinase 1) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)
|
ER positive
5ms
HNRNPA2B1 confers immune escape of non-small cell lung cancer through targeting lactate/ferroptosis. (PubMed, Cell Death Dis)
Furthermore, HNRNPA2B1 targeted the LDHA mRNA m6A modified site to enhance LDHA mRNA stability and lactate accumulation, thereby assisted NSCLC cells to evade CD8+ T antitumor immunity and reduced IFN-γ secretion by CD8+ T. Furthermore, IFN-γ could stimulate ferroptosis of NSCLC cells. Taken together, these findings revealed an important role for HNRNPA2B1 on NSCLC immune escape and ferroptosis resistance, which provided novel insight into m6A modification in NSCLC.
Journal
|
LDHA (Lactate dehydrogenase A) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)
6ms
tRNA-Derived Fragment tRF-22 Promotes Immunosuppression by Inhibiting HnRNPAB Ubiquitination in Esophageal Squamous Cell Carcinoma. (PubMed, Adv Sci (Weinh))
Overall, a tRF-22-hnRNPAB-TGFβ2-PMN-MDSCs-CD8+ T cell pathway is identified that drives immunosuppression and tumor growth. Targeting tRF-22 may be a promising strategy to improve immunotherapy efficacy in ESCC.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • TGFB2 (Transforming Growth Factor Beta 2)
7ms
Unraveling the impact of VHL exon 2 mutations in erythrocytosis or von Hippel-Lindau disease identified RNA-binding proteins involved in VHL splicing. (PubMed, Am J Hum Genet)
Our findings reveal the limitations of current splicing-prediction tools in recognizing exonic-splicing enhancer (ESE) or silencer (ESS) sequences and suggest that mutations can differentially affect disease phenotypes by influencing both splicing and protein stability. These insights enhance our understanding of the molecular mechanisms underlying VHL-associated disorders and expand the landscape of regulatory elements and protein factors involved in VHL splicing regulation.
Journal
|
VHL (von Hippel-Lindau tumor suppressor) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)
|
VHL mutation
7ms
Heterogeneous nuclear ribonucleoprotein A/B drives gastric cancer and epithelial-mesenchymal transition via the Akt-GSK3β-Wnt pathway. (PubMed, Mol Pharmacol)
SIGNIFICANCE STATEMENT: This exploratory study reveals that heterogeneous nuclear ribonucleoprotein A/B is associated with gastric cancer progression and epithelial-mesenchymal transition through its potential modulation of the Akt-GSK3β-Wnt signaling pathway. Targeting heterogeneous nuclear ribonucleoprotein A/B could offer novel therapeutic approaches for improving treatment outcomes in gastric cancer, highlighting its potential as a biomarker for disease prognosis.
Journal
|
CDH1 (Cadherin 1) • VIM (Vimentin) • CDH2 (Cadherin 2) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)
9ms
Journal
|
PCNA (Proliferating cell nuclear antigen) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)
9ms
Extracellular vesicle-mediated transmission of circPDLIM5 promotes lymphatic metastasis in prostate cancer. (PubMed, J Exp Clin Cancer Res)
Subsequently, EVs were transmitted to human lymphatic endothelial cells, and EVs carrying circPDLIM5 could then directly interact with the transcription factor Yin Yang 1 to enhance the expression of Prospero homeobox 1, which is crucial for the formation, differentiation, and maturation of lymphatic vessels. Our findingshighlight the importance of a molecular mechanism mediated by EVs carrying circPDLIM5that is involved in lymphangiogenesis and LN metastasis in PCa; as a result, EVscarrying circPDLIM5 may be an attractive therapeutic target for LN-metastatic PCa.
Journal
|
VEGFC (Vascular Endothelial Growth Factor C) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • YY1 (YY1 Transcription Factor)
10ms
CircSRPK1 mediated by the exon junction complex promotes gastric cancer progression by interacting with hnRNP A2B1 to regulate RON mRNA alternative splicing. (PubMed, Cancer Lett)
Additionally, MAGOH knockdown rescued circSRPK1-mediated RONΔ160 formation and GC malignancy. Overall, our research revealed a novel mechanism by which the MAGOH-circSRPK1-hnRNPA2B1-RONΔ160 axis regulated GC cell proliferation and metastasis, broadening the current understanding of circRNA-mediated regulation of tumor progression through aberrant alternative splicing.
Journal
|
HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • EIF4A3 (Eukaryotic Translation Initiation Factor 4A3) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1) • SRPK1 (SRSF Protein Kinase 1)
1year
KAP1 promotes gastric adenocarcinoma progression by activating Hippo/YAP1 signaling via binding to HNRNPAB. (PubMed, Cancer Lett)
These findings establish KAP1 as a critical driver of tumor progression in GAC through YAP1 regulation and HNRNPAB interaction, highlighting its potential therapeutic target. This study advances our understanding and offers a preclinical framework to improve outcomes for GAC.
Journal
|
YAP1 (Yes associated protein 1) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B)
1year
Effective Immobilization of hnRNPA2B1 Protein in a PEI Layer on a QCM Gold Electrode. (PubMed, Langmuir)
Increasing the ionic strength to 0.1 mM significantly enhanced protein adsorption (Δf/n = -69 Hz). These findings emphasize the role of the PEI layer structure in optimizing protein immobilization, paving the way for further exploration of RBPs and their ligands.
Journal
|
HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)